Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae

Pharmacotherapy

Volumn 20, Issue 11 I, 2000, Pages 1310-1317

  Kays, M B ^a   Conklin, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATION; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; STREPTOCOCCUS PNEUMONIAE;

EID: 0033755095     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.17.1310.34899     Document Type: Article

References (68)

1. Community-acquired pneumonia: Epidemiology, etiology, treatment
2. Communityacquired pneumonia in adults: Guidelines for management
3. Acute community-acquired sinusitis
4. Acute exacerbations of chronic bronchitis
5. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens
6. The epidemiology of community-acquired pneumonia among hospitalized patients
7. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland
8. Antimicrobial resistance in Streptococcus pneumoniae: An overview
9. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae
10. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program
11. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study
12. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998
13. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study
14. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to oral agents: Results of a 1998 US outpatient surveillance study
15. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
16. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones.'
17. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
18. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
19. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
20. Expanded activity and utility of the new fluoroquinolones: A review
21. Impact of different statistical methodologies on the evaluation of the in vitro MICs for Bacteroides fragilis of selected cephalosporins and cephamycins
22. In vitro activity and pharmacodynamics of oral β-lactam antibiotics against Streptococcus pneumoniae from southeast Missouri
23. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers
24. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers
25. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses
26. The comparative pharmacokinetics and tissue penetration of singledose ciprofloxacin 400 mg iv and 750 mg po
27. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects
28. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects
29. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases
30. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects
31. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral and intravenous doses
32. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers
33. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers
34. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers
35. Oral bioavailability of trovafloxacin with and without food in healthy volunteers
36. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin
37. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin
38. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
39. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment
40. Population pharmacokinetics of gatifloxacin in adults with acute bacterial exacerbation of chronic bronchitis
41. Effect of a high-fat meal on the bioavailability of gatifloxacin in healthy volunteers
42. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium
43. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men
44. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults
45. The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects
46. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin
47. Pharmacokinetics of clinafloxacin following oral and intravenous single and multiple dosing in volunteers
48. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
49. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
50. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
51. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae
52. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia
53. Pneumococcal meningitis during intravenous ciprofloxacin therapy
54. Inappropriate use of oral ciprofloxacin
55. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin
56. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin
57. The failure of ciprofloxacin to prevent the progression of Streptococcus pneumoniae infections to meningitis
58. Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro dynamic model
59. Treating community-acquired pneumonia with once-daily gatifloxacin vs. once daily levofloxacin
60. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results
61. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double-blind study
62. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
63. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
64. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
65. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
66. Three levofloxacin treatment failures of pneumococcal respiratory tract infections
67. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae